• 1.

    West S, Munoz B, Bobo L, Quinn TC, Mkocha H, Lynch M, Mmbaga BB, Viscidi R, 1993. Nonocular Chlamydia infection and risk of ocular reinfection after mass treatment in a trachoma hyperendemic area. Invest Ophthalmol Vis Sci 34: 31943198.

    • Search Google Scholar
    • Export Citation
  • 2.

    Stocks ME, Ogden S, Haddad D, Addiss DG, McGuire C, Freeman MC, 2014. Effect of water, sanitation, and hygiene on the prevention of trachoma: a systematic review and meta-analysis. PLoS Med 11: e1001605.

    • Search Google Scholar
    • Export Citation
  • 3.

    Solomon AW et al. 2003. Strategies for control of trachoma: observational study with quantitative PCR. Lancet 362: 198204.

  • 4.

    House JI et al. 2009. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster-randomised trial. Lancet 373: 11111118.

    • Search Google Scholar
    • Export Citation
  • 5.

    Abdou A, Munoz BE, Nassirou B, Kadri B, Moussa F, Baare I, Riverson J, Opong E, West SK, 2010. How much is not enough? A community randomized trial of a Water and Health Education programme for Trachoma and Ocular C. trachomatis infection in Niger. Trop Med Int Health 15: 98104.

    • Search Google Scholar
    • Export Citation
  • 6.

    Gebre T et al. 2012. Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial. Lancet 379: 143151.

    • Search Google Scholar
    • Export Citation
  • 7.

    Teklehaimanot HD, Teklehaimanot A, 2013. Human resource development for a community-based health extension program: a case study from Ethiopia. Hum Resour Health 11: 39.

    • Search Google Scholar
    • Export Citation
  • 8.

    Banteyerga H, 2011. Ethiopia’s health extension program: improving health through community involvement. MEDICC Rev 13: 4649.

  • 9.

    Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR, 1987. A simple system for the assessment of trachoma and its complications. Bull World Health Organ 65: 477483.

    • Search Google Scholar
    • Export Citation
  • 10.

    Solomon AW et al. 2004. Mass treatment with single-dose azithromycin for trachoma. N Engl J Med 351: 19621971.

  • 11.

    West ES, Munoz B, Mkocha H, Holland MJ, Aguirre A, Solomon AW, Bailey R, Foster A, Mabey D, West SK, 2005. Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community. Invest Ophthalmol Vis Sci 46: 8387.

    • Search Google Scholar
    • Export Citation
  • 12.

    Diamant J, Benis R, Schachter J, Moncada J, Pang F, Jha HC, Bhatta RC, Porco T, Lietman T, 2001. Pooling of Chlamydia laboratory tests to determine the prevalence of ocular Chlamydia trachomatis infection. Ophthalmic Epidemiol 8: 109117.

    • Search Google Scholar
    • Export Citation
  • 13.

    Stoller NE et al. 2011. Efficacy of latrine promotion on emergence of infection with ocular Chlamydia trachomatis after mass antibiotic treatment: a cluster-randomized trial. Int Health 3: 7584.

    • Search Google Scholar
    • Export Citation
  • 14.

    Lakew T et al. 2009. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Negl Trop Dis 3: e376.

  • 15.

    Burton MJ et al. 2003. Which members of a community need antibiotics to control trachoma? Conjunctival Chlamydia trachomatis infection load in Gambian villages. Invest Ophthalmol Vis Sci 44: 42154222.

    • Search Google Scholar
    • Export Citation
  • 16.

    Harding-Esch EM et al. 2010. Trachoma prevalence and associated risk factors in the Gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Negl Trop Dis 4: e861.

    • Search Google Scholar
    • Export Citation
  • 17.

    Ayele B et al. 2011. Risk factors for ocular chlamydia after three mass azithromycin distributions. PLoS Negl Trop Dis 5: e1441.

  • 18.

    Amza A et al. 2012. Community risk factors for ocular Chlamydia infection in Niger: pre-treatment results from a cluster-randomized trachoma trial. PLoS Negl Trop Dis 6: e1586.

    • Search Google Scholar
    • Export Citation
  • 19.

    Ejere HO, Alhassan MB, Rabiu M, 2015. Face washing promotion for preventing active trachoma. Cochrane Database Syst Rev 4: CD003659.

  • 20.

    West S, Munoz B, Lynch M, Kayongoya A, Chilangwa Z, Mmbaga BB, Taylor HR, 1995. Impact of face-washing on trachoma in Kongwa, Tanzania. Lancet 345: 155158.

    • Search Google Scholar
    • Export Citation
  • 21.

    Resnikoff S, Peyramaure F, Bagayogo CO, Huguet P, 1995. Health education and antibiotic therapy in trachoma control. Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique 72: 101110.

    • Search Google Scholar
    • Export Citation
  • 22.

    Peach H, Piper S, Devanesen D, Dixon B, Jeffries C, Braun P, Nelson D, Kruger G, Boulden H, 1987. Northern Territory Trachoma Control and Eye Health Committee’s Randomised Controlled Trial of the Effect of Eye Drops and Eye Washing on Follicular Trachoma Among Aboriginal Children. Darwin, Australia: Menzies School of Health Research.

    • Search Google Scholar
    • Export Citation
  • 23.

    Edwards T, Cumberland P, Hailu G, Todd J, 2006. Impact of health education on active trachoma in hyperendemic rural communities in Ethiopia. Ophthalmology 113: 548555.

    • Search Google Scholar
    • Export Citation
  • 24.

    Atik B, Thanh TT, Luong VQ, Lagree S, Dean D, 2006. Impact of annual targeted treatment on infectious trachoma and susceptibility to reinfection. JAMA 296: 14881497.

    • Search Google Scholar
    • Export Citation
  • 25.

    Hulland K, Martin N, Dreibelbis R, 2015. What Factors Affect Sustained Adoption of Safe Water, Hygiene and Sanitation Technologies? A Systematic Review of Literature. Available at: https://eppi.ioe.ac.uk/cms/Portals/0/PDF%20reviews%20and%20summaries/WASH%20technologies%202015%20Hulland%20report.pdf?ver=2015-06-10-141853-910. Accessed November 13, 2020.

    • Search Google Scholar
    • Export Citation
 
 
 

 

 

 

 

 

 

Community Hand-Dug Wells for Trachoma: A Cluster-Randomized Trial

View More View Less
  • 1 The Carter Center Ethiopia, Addis Ababa, Ethiopia;
  • | 2 Francis I Proctor Foundation, University of California, San Francisco, San Francisco, California;
  • | 3 The Carter Center, Atlanta, Georgia;
  • | 4 Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California;
  • | 5 Department of Ophthalmology, University of California, San Francisco, San Francisco, California

ABSTRACT

The WHO recommends improving access to water as part of a comprehensive strategy for elimination of trachoma as a public health problem; however, this recommendation is not based on evidence from randomized trials. In a region of Ethiopia with hyperendemic trachoma, seven communities were randomized to a hand-dug well (HDW) and seven communities to no intervention to determine the impact of HDWs on the community prevalence of ocular chlamydia infection (primary prespecified outcome). All communities continued to receive government hygiene and sanitation services and outreach. Participants were not masked, given the nature of the intervention, but laboratory personnel were masked to treatment allocation. Hand-dug wells were successfully built in six of the seven communities; five of these wells were still functional at the conclusion of the trial. At the end of the trial, an average of 74% of households reported traveling < 30 minutes to collect water in the HDW arm, compared with 45% in the control arm, and the daily volume of water used for hygiene was similar (e.g., mean of 0.7 L per person in each arm). The pseudo-median prevalence of ocular chlamydia among 0- to 5-year old children at the 24-month visit was 23% in the HDW group and 13% in the control group (P > 0.99). This small cluster-randomized trial provided no evidence to suggest that simply constructing HDWs, in the absence of other hygiene promotion activities, is effective for reducing transmission of ocular chlamydia.

    • Supplemental Materials (DOC 91.00 KB)

Author Notes

Address correspondence to Jeremy D. Keenan, 513 Parnassus Ave., Box 0412, University of California, San Francisco San Francisco, CA 94143. E-mail: jeremy.keenan@ucsf.edu

Financial support: The main funders of the trial were That Man May See and the National Eye Institute (grant U10 EY016214). Additional funding was provided by the Bernard Osher Foundation, the Harper Inglis Trust, the Bodri Foundation, the Proctor Foundation’s South Asia Research Fund, and Research to Prevent Blindness. The trachoma control program in Amhara is supported by the Carter Center, Amhara Regional Health Bureau, the Lions-Carter Center SightFirst Initiative, and many individual donors.

Authors’ addresses: Solomon Aragie, Sintayehu Gebresillasie, Ambahun Chernet, Ayalew Shiferaw, Zerihun Tadesse, and Mulat Zerihun, The Carter Center Ethiopia, Addis Ababa, Ethiopia, E-mails: solomon.aragie@cartercenter.org, sintayehugs@gmail.com, ambahun.chernet@cartercenter.org, ayalew.shiferaw@cartercenter.org, zerihun.tadesse@cartercenter.org, and mulat.zerihun@cartercenter.org. Nicole E. Varnado, Sun Y. Cotter, Dionna M. Wittberg, and Zhaoxia Zhou, Kristen Aiemjoy, and Jeremy D. Keenan, Francis I Proctor Foundation, University of California, San Francisco, San Francisco, CA, E-mails: nicole.e.varnado@kp.org, sun.cotter@ucsf.edu, dionna.wittberg@ucsf.edu, zhaoxia.zhou@ucsf.edu, kaiemjoy@stanford.edu and jeremy.keenan@ucsf.edu. Elizabeth Kelly Callahan and Scott D. Nash, The Carter Center, Atlanta, GA, E-mails: kelly.callahan@cartercenter.org and scott.nash@cartercenter.org.

These authors contributed equally to this work.

Save